Deletions in env gene of HIV-1 in AIDS patients treated with highly active antiretroviral therapy (HAART)

Journal of Medical Virology

Volumn 71, Issue 2, 2003, Pages 167-172

  Saurya, Shreesh ^a   Lichtenstein, Zelman ^b   Karpas, Abraham ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b St Wolfgangs Platz   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Combination therapy; Discordance; Env; HAART; High CD4+ T cells; High viral load; Virological failure

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; ENVELOPE GENE; GENE DELETION; GENOME ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE COUNT; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; T LYMPHOCYTE; VIRUS DETECTION; VIRUS ENVELOPE; VIRUS GENE; VIRUS LOAD; VIRUS MUTANT; VIRUS PARTICLE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASE SEQUENCE; GENES, ENV; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0041854725     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10459     Document Type: Article

References (22)

1. Blair WS, Lin PF, Meanwell NA, Wallace OB. 2000. HIV-1 entry: an expanding portal for drug discovery. Drug Discov Today 5:183-194.
2. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. 2000. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 181:946-953.
3. Dubay JW, Roberts SJ, Hahn BH, Hunter E. 1992. Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol 66:6616-6625.
4. Fang G, Weiser B, Visosky AA, Townsend L, Burger H. 1996. Molecular cloning of full-length HIV-1 genomes directly from plasma viral RNA. J Acquir Immune Defic Syndr Hum Retrovirol 12:352-357.
5. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, et al. 1990. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med 112:727-737.
6. Fransen K, Zhong P, De Beenhouwer H, Carpels G, Peeters M, Louwagie J, Janssens W, Piot P, van der Groen G. 1994. Design and evaluation of new, highly sensitive and specific primers for polymerase chain reaction detection of HIV-1 infected primary lymphocytes. Mol Cell Probes 8:317-322.
7. Gross-Bellard M, Oudet P, Chambon P. 1973. Isolation of high-molecular-weight DNA from mammalian cells. Eur J Biochem 36: 32-38.
8. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA, Richman DD. 1998. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. Jama 280: 35-41.
9. Huang X. 1994. On global sequence alignment. Biosciences 10:227-235.
10. Karpas A, Gillson W, Bevan PC, Oates JK. 1985. Lytic infection by British AIDS virus and development of rapid cell test for antiviral antibodies. Lancet 2:695-697.
11. Kaufmann D, Pantaleo G, Sudre P, Telenti A. 1998. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 351:723-724.
12. Larder BA, Darby G, Richman DD. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
13. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. 1985. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82:7096-7100.
14. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352:1725-1730.
15. Palella FJ Jr. Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
16. Ratner L, Vander Heyden N, Garcia J, Polinsky M, Westervelt P, Becich M. 1991. Formation of noninfectious HIV-1 virus particles lacking a full-length envelope protein. AIDS Res Hum Retroviruses 7:287-294.
17. Rice PL, Bleasby A. 2000. EMBOSS: The European molecular biology open software suite. Trends Geneti 16:276-277.
18. Sadaie MR, Kalyanaraman VS, Mukopadhayaya R, Tschachler E, Gallo RC, Wong-Staal F. 1992. Biological characterization of noninfectious HIV-1 particles lacking the envelope protein. Virology 187:604-611.
19. Saurya S, Lichtenstein Z, Karpas A. 2002. Characterization of pol, vif, vpr, and vpu genes of HIV type 1 in AIDS patients with high viral load and stable CD4+ T cell counts on combination therapy. AIDS Res Hum Retrovir 18:1151-1155.
20. Smith TF, Waterman MS. 1981. dentification of common molecular subsequences. J Mol Biol 147:195-197.
21. Staden R, Beal KF, Bonfield JK. 2000. The Staden package, 1998. Methods Mol Biol 132:115-130.
22. Ugolini S, Mondor I, Sattentau QJ. 1999. HIV-1 attachment: another look. Trends Microbiol 7:144-149.